Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry64(5), 543–552 (2007).
   PubMed Web of Science ®Google Scholar
• Akiskal HS, Akiskal KK, Lancrenon S et al. Validating the bipolar spectrum in the French National EPIDEP Study: overview of the phenomenology and relative prevalence of its clinical prototypes. J. Affect. Disord.96(3), 197–205 (2006).
   PubMed Web of Science ®Google Scholar
• Faravelli C, Rosi S, Scarpato MA, Lampronti L, Amedei SG, Rana N. Threshold and subthreshold bipolar disorders in the Sesto Fiorentino Study. J. Affect. Disord.94(1–3), 111–119 (2006).
   PubMed Web of Science ®Google Scholar
• Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rössler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J. Affect. Disord.73(1–2), 133–146 (2003).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: reanalysis of the ECA database taking into account subthreshold cases. J. Affect. Disord.73(1–2), 123–131 (2003).
   PubMed Web of Science ®Google Scholar
• Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr. Clin. North Am.22(3), 517–534 (1999).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry159(4 Suppl.), 1–50 (2002).
   Web of Science ®Google Scholar
• Society for Manic-Depressive Disorder. National survey of NDMDA members finds long delay in diagnosis of manic-depressive illness. Hosp. Community Psychiatry44, 800–801 (1993).
   PubMedGoogle Scholar
• Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J. Clin. Psychiatry61(10), 804–808 (2000).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. Bipolar spectrum disorder: improving its recognition and diagnosis. J. Clin. Psychiatry62(Suppl. 14), 5–9 (2001).
   PubMed Web of Science ®Google Scholar
• Suppes T, Leverich GS, Keck PE et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J. Affect. Disord.67(1–3), 45–59 (2001).
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Ko JY, Goodwin FK. “Cade’s disease” and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can. J. Psychiatry47(2), 125–134 (2002).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry64(2), 161–174 (2003).
   PubMed Web of Science ®Google Scholar
• Morselli PL, Elgie R; GAMIAN-Europe. GAMIAN-Europe/BEAM survey I – global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. Bipolar Disord.5(4), 265–278 (2003).
   PubMed Web of Science ®Google Scholar
• Berk M, Dodd S, Callaly P et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J. Affect. Disord.103(1–3), 181–186 (2007).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. Screening for bipolar disorder. Am. J. Manag. Care13(Suppl. 7), S164–S169 (2007).
   PubMed Web of Science ®Google Scholar
• Cha B, Kim JH, Ha TH, Chang JS, Ha K. Polarity of the first episode and time to diagnosis of bipolar I disorder. Psychiatry Invest.6(2), 96–101 (2009).
   PubMed Web of Science ®Google Scholar
• Altamura AC, Buoli M, Albano A, Dell’Osso B. Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. Int. Clin. Psychopharmacol.25, 172–179 (2010).
   PubMed Web of Science ®Google Scholar
• Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA276(4), 293–299 (1996).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry60(3), 261–269 (2003).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry59(6), 530–537 (2002).
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Kupka RW, Hellemann G et al. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Outcome Network. Am. J. Psychiatry167(6), 708–715 (2010).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ, Soczynska JK et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr. Serv.57(8), 1140–1144 (2006).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Bottas A, Bordbar K, Konarski JZ, Kennedy SH. Anxiety disorders and bipolar disorder: a review. Bipolar Disord.8(6), 665–676 (2006).
   PubMed Web of Science ®Google Scholar
• Vornik LA, Brown ES. Management of comorbid bipolar disorder and substance abuse. J. Clin. Psychiatry67(Suppl. 7), 24–30 (2006).
   PubMed Web of Science ®Google Scholar
• Fan AH, Hassell J. Bipolar disorder and comorbid personality psychopathology: a review of the literature. J. Clin. Psychiatry69(11), 1794–1803 (2008).
   PubMed Web of Science ®Google Scholar
• Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. Health. Qual. Life Outcomes3, 72 (2005).
   PubMedGoogle Scholar
• Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: an extensive review. Psychother. Psychosom.78(5), 285–297 (2009).
   PubMed Web of Science ®Google Scholar
• Berk L, Hallam KT, Colom F et al. Enhancing medication adherence in patients with bipolar disorder. Hum. Psychopharmacol. Clin. Exp.25, 1–16 (2010).
   PubMed Web of Science ®Google Scholar
• Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar. Disord.12, 1–9 (2010).
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry68(6), 899–907 (2007).
   PubMed Web of Science ®Google Scholar
• Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J. Affect. Disord.68, 167–181 (2002).
   PubMed Web of Science ®Google Scholar
• Osby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry58(9), 844–850 (2001).
   PubMed Web of Science ®Google Scholar
• Callaghan RC, Khizar A. The incidence of cardiovascular morbidity among patients with bipolar disorder: a population-based longitudinal study in Ontario, Canada. J. Affect. Disord.122(1–2), 118–123 (2010).
   PubMed Web of Science ®Google Scholar
• Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr. Serv.60(2), 147–156 (2009).
   PubMed Web of Science ®Google Scholar
• Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? Curr. Psychiatr. Rep.11, 475–480 (2009).
   PubMed Web of Science ®Google Scholar
• Perron BE, Howard MO, Nienhuis JK, Bauer MS, Woodward AT, Kilbourne AM. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry70(10), 1407–1415 (2009).
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord.11(6), 657–662 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson WK, Kupfer DJ, Fagiolini A, Scott JA, Frank E. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J. Clin. Psychiatry67(5), 783–788 (2006).
   PubMed Web of Science ®Google Scholar
• Kilbourne AM, Cornelius JR, Han X et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord.6, 368–373 (2004).
   PubMed Web of Science ®Google Scholar
• Diaz FJ, James D, Botts S, Maw L, Susce MT, de Leon J. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord.11(2), 154–165 (2009).
   PubMed Web of Science ®Google Scholar
• Chuang HT, Mansell C, Patten SB. Lifestyle characteristics of psychiatric outpatients. Can. J. Psychiatry53(4), 260–266 (2008).
   PubMed Web of Science ®Google Scholar
• Kilbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord.9(5), 443–452 (2007).
   PubMed Web of Science ®Google Scholar
• Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA284(20), 2606–2610 (2000).
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry70(Suppl. 4), 1–46 (2009).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ostacher MJ, Miklowitz DJ et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J. Clin. Psychiatry71(3), 296–303 (2010).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum. Psychopharmacol.23(2), 95–105 (2008).
   PubMed Web of Science ®Google Scholar
• Clatworthy J, Bowskill R, Rank T, Parham R, Horne R. Adherence to medication in bipolar disorder: a qualitative study exploring the role of patients’ beliefs about the condition and its treatment. Bipolar Disord.9(6), 656–664 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med. Care45(6), 545–552 (2007).
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Elhaj O, Youngstrom EA et al. Treatment adherence in individuals with rapid cycling bipolar disorder: results from a clinical-trial setting. J. Clin. Psychopharmacol.27(4), 412–414 (2007).
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr. Serv.58(6), 855–863 (2007).
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord.8(3), 232–241 (2006).
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J. Clin. Psychiatry63(5), 384–390 (2002).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL, Strakowski SM et al. Factors associated with pharmacologic noncompliance in patients with mania. J. Clin. Psychiatry57(7), 292–297 (1996).
   PubMed Web of Science ®Google Scholar
• Zeber JE, McCarthy JF, Bauer MS, Kilbourne AM. Datapoints: self-reported access to general medical and psychiatric care among veterans with bipolar disorder. Psychiatr. Serv.58(6), 740 (2007).
   PubMedGoogle Scholar
• Kilbourne AM, McCarthy JF, Post EP et al. Access to and satisfaction with care comparing patients with and without serious mental illness. Int. J. Psychiatry Med.36(4), 383–399 (2006).
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Parker C, Coupland C, Vinogradova Y. Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart93(10), 1256–1262 (2007).
   PubMedGoogle Scholar
• Frayne SM, Halanych JH, Miller DR et al. Disparities in diabetes care: impact of mental illness. Arch. Intern. Med.165(22), 2631–2638 (2005).
   PubMed Web of Science ®Google Scholar
• Cradock-O’Leary J, Young AS, Yano EM, Wang M, Lee ML. Use of general medical services by VA patients with psychiatric disorders. Psychiatr. Serv.53(7), 874–878 (2002).
   PubMed Web of Science ®Google Scholar
• Slatkin M. Exchangeable models of complex inherited diseases. Genetics179(4), 2253–2261 (2008).
   PubMedGoogle Scholar
• Centorrino F, Mark TL, Talamo A, Oh K, Chang J. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. J. Clin. Psychopharmacol.29(6), 595–600 (2009).
   PubMed Web of Science ®Google Scholar
• Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. The economic impact of bipolar disorder in an employed population from an employer perspective. J. Clin. Psychiatry67(8), 1209–1218 (2006).
   PubMed Web of Science ®Google Scholar
• Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord.4(6), 398–405 (2002).
   PubMed Web of Science ®Google Scholar
• Woods SW. The economic burden of bipolar disorder. J. Clin. Psychiatry61(Suppl. 13), 38–41 (2000).
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness – 1991. Soc. Psychiatry Psychiatr. Epidemiol.30(5), 213–219 (1995).
   PubMed Web of Science ®Google Scholar
• Magliano L, Orrico A, Fiorillo A et al. Family burden in bipolar disorders: results from the Italian Mood Disorders Study (IMDS). Epidemiol. Psychiatr. Soc.18(2), 137–146 (2009).
   PubMedGoogle Scholar
• Fajutrao L, Locklear J, Priaulx J, Heyes A. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin. Pract. Epidemiol. Ment. Health.5, 3 (2009).
   PubMedGoogle Scholar
• van der Voort TY, Goossens PJ, van der Bijl JJ. Burden, coping and needs for support of caregivers for patients with a bipolar disorder: a systematic review. J. Psychiatr. Ment. Health Nurs.14(7), 679–687 (2007).
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J. Biol. Psychiatry10(2), 85–116 (2009).
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord.11(3), 225–255 (2009).
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health. Bipolar disorder. The management of bipolar disorder in adults, children, and adolescents, in primary and secondary care. British Psychological Society, Royal College of Psychiatrists, Leicester, UK, 592 (2006).
   Google Scholar
• Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. J. Psychopharmacol.23(4), 346–388 (2009).
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet373(9657), 31–41 (2009).
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin. Ther.31(1), 1345–1359 (2009).
   PubMed Web of Science ®Google Scholar
• Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J. Psychiatr. Pract.13(1), 13–24 (2007).
   PubMedGoogle Scholar
• Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry10(1), 79–104 (2005).
   PubMed Web of Science ®Google Scholar
• Serretti A, De Ronchi D, Lorenzi C, Berardi D. New anti psychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem.11, 343–358 (2004).
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Swartz MS et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development Schizophr. Bull.29(1), 15–31 (2003).
   PubMed Web of Science ®Google Scholar
• Tandon R, Jibson MD. Efficacy of newer generation anti psychotics in the treatment of schizophrenia. Psychoneuroendocrinology28(Suppl. 1), 9–26 (2003).
   PubMed Web of Science ®Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ321(7273), 1371–1376 (2000).
   PubMed Web of Science ®Google Scholar
• Lafuente A, Bernardo M, Mas S et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res.161(2), 131–141 (2008).
   PubMedGoogle Scholar
• Tunca Z, Resmi H, Ozkara HA et al. Increased hexosaminidase activity in antipsychotic-induced extrapyramidal side effects: possible association with higher occurrence in bipolar disorder patients. Prog. Neuropsychopharmacol. Biol. Psychiatry32(5), 1214–1220 (2008).
   PubMedGoogle Scholar
• Tohen M, Zhang F, Taylor CC et al. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J. Affect. Disord.65, 85–93 (2001).
   PubMedGoogle Scholar
• Harma BJ, Nasrallah HA, Clancy J et al. Psychiatric diagnosis and risk for tardive dyskinesia. Arch. Gen. Psychiatry40, 346–347 (1993).
   Google Scholar
• Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry7, 40 (2007).
   PubMed Web of Science ®Google Scholar
• Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry60(12), 1218–1226 (2003).
   PubMed Web of Science ®Google Scholar
• Niufan G, Tohen M, Qiuqing A et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J. Affect. Disord.105(1–3), 101–108 (2008).
   PubMed Web of Science ®Google Scholar
• Buckley PF, Paulsson B, Brecher M. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine. J. Affect. Disord.100(Suppl. 1), S33–S43 (2007).
   PubMedGoogle Scholar
• McIntyre RS, Konarski JZ, Jones M, Paulsson B. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J. Affect. Disord.100(Suppl. 1), S5–S14 (2007).
   PubMed Web of Science ®Google Scholar
• Sokolski KN, Denson TF. Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Prog. Neuropsychopharmacol. Biol. Psychiatry27(5), 863–866 (2003).
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry59(1), 62–69 (2002).
   PubMed Web of Science ®Google Scholar
• Cookson J. Use of antipsychotic drugs and lithium in mania. Br. J. Psychiatry178(Suppl. 41), S148–S156 (2001).
   PubMedGoogle Scholar
• Bond DJ, Noronha MM, Kauer-Sant’Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J. Clin. Psychiatry69(10), 1589–1601 (2008).
   PubMed Web of Science ®Google Scholar
• Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr.13(9), 790–795 (2008).
   PubMedGoogle Scholar
• Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry161(9), 1537–1547 (2004).
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J. Biol. Psychiatry11(2), 81–109 (2010).
   PubMed Web of Science ®Google Scholar
• Azorin JM, Kaladjian A. An update on the treatment of bipolar depression. Expert Opin. Pharmacother.10(2), 161–172 (2009).
   PubMed Web of Science ®Google Scholar
• Nivoli AM, Colom F, Murru A et al. New treatment guidelines for acute bipolar depression: a systematic review. J. Affect. Disord.129(1–3), 14–26 (2010).
   PubMedGoogle Scholar
• Suppes T, Vieta E, Liu S, Brecher M, Paulsson B; Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127). Am. J. Psychiatry166(4), 476–488 (2009).
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord.11(Suppl. 2), 45–54 (2009).
   PubMedGoogle Scholar
• Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord.9(4), 394–412 (2007).
   PubMed Web of Science ®Google Scholar
• Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry163(2), 247–256 (2006).
   PubMed Web of Science ®Google Scholar
• Rosa AR, Franco C, Torrent C et al. Ziprasidone in the treatment of affective disorders: a review. CNS Neurosci. Ther.14(4), 278–286 (2009).
   Google Scholar
• Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol.425(3), 197–201 (2001).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry64(Suppl. 19), 6–12 (2003).
   Google Scholar
• Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann. Pharmacother.36(5), 839–851 (2002).
   PubMed Web of Science ®Google Scholar
• Davis R, Markham A. Ziprasidone. CNS Drugs8(2), 153–159 (1997).
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci.68(1), 29–39 (2000).
   PubMed Web of Science ®Google Scholar
• Segal J, Walton S, Clark H, Berk M. Pharmacotherapy of mania: a review. Int. J. Psychiatry Clin. Pract.4, 171–193 (2000).
   PubMed Web of Science ®Google Scholar
• Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy21(6), 717–730 (2001).
   PubMed Web of Science ®Google Scholar
• Mamo D, Kapur S, Shammi CM et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry161(5), 818–825 (2004).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Lieberman JA, Weiden PJ et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr.10(11 Suppl. 17), 1–20 (2005).
   PubMed Web of Science ®Google Scholar
• Prakash C, Kamel A, Gummerus J, Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos.25(7), 863–872 (1997).
   PubMed Web of Science ®Google Scholar
• Hamelin BA, Allard S, Laplante L et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy18(1), 9–15 (1998).
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Glue P, Alderman J, Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol. Bull.40(3), 58–68 (2007).
   PubMed Web of Science ®Google Scholar
• Gandelman K, Alderman JA, Glue P et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J. Clin. Psychiatry70(1), 58–62 (2009).
   PubMed Web of Science ®Google Scholar
• Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J. Clin. Psychopharmacol.23(3), 229–232 (2003).
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin. Pharmacokinet.44(11), 1117–1133 (2005).
   PubMed Web of Science ®Google Scholar
• Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev.13(2), 137–177 (2007).
   PubMedGoogle Scholar
• Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr. Serv.59(10), 1207–1210 (2008).
   PubMed Web of Science ®Google Scholar
• Berk L, Hallam KT, Colom F et al. Enhancing medication adherence in patients with bipolar disorder. Hum. Psychopharmacol.25(1), 1–16 (2010).
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J. Clin. Psychopharmacol.25(4), 388–391 (2005).
   PubMed Web of Science ®Google Scholar
• Citrome L, Reist C, Palmer L et al. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr. Res.108(1–3), 238–244 (2009).
   PubMedGoogle Scholar
• Citrome L, Reist C, Palmer L et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Schizophr. Res.115(2–3), 115–120 (2009).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry160(4), 741–748 (2003).
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). Biometrics Research, New York State Psychiatric Institute, NY, USA (2002).
   Google Scholar
• Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry35(7), 837–844 (1978).
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76–338. US Department of Health, Education, and Welfare, Washington, DC, USA, 534–537 (1976).
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull.13(2), 261–276 (1987).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J. Clin. Psychopharmacol.25(4), 301–310 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry23, 56–62 (1960).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry134, 382–389 (1979).
   PubMed Web of Science ®Google Scholar
• Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J. Psychopharmacol.24(4), 547–558 (2010).
   PubMed Web of Science ®Google Scholar
• Weisler R, Warrington L, Dunn J, Giller EL, Mandel FS. Adjunctive ziprasidone in bipolar mania: short and long-term data. Presented at: 157th Annual Meeting of the American Psychiatric Association. New York, NY, USA, 1–6 May 2004.
   Google Scholar
• Potkin SG, Keck PE, Giller E et al. Ziprasidone in bipolar mania: efficacy across patient subgroups. Presented at: 157th Annual Meeting of the American Psychiatric Association. New York, NY, USA, 1–6 May 2004.
   Google Scholar
• Stahl S, Lombardo I, Loebel A, Mandel FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J. Affect. Disord.122(1–2), 39–45 (2010).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI, Faedda GL, Swann AC. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am. J. Psychiatry149(12), 1633–1644 (1992).
   PubMed Web of Science ®Google Scholar
• Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. J. Psychiatr. Res.44(1), 8–14 (2010).
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Salmán E, Mech A et al. Ziprasidone monotherapy in bipolar II depression: an open trial. J. Affect. Disord.118(1–3), 205–208 (2009).
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol.32(1), 50–55 (1959).
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol. Bull.29(2), 321–326 (1993).
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry4, 561–571 (1961).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J. Clin. Psychiatry71(2), 130–137 (2010).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Versiani M, Warrington L, Loebel AD, Horne RL. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J. Clin. Psychiatry70(6), 844–851 (2009).
   PubMed Web of Science ®Google Scholar
• Centorrino F, MacLean E, Salvatore P et al. Ziprasidone: first year experience in a hospital setting. J. Psychiatr. Pract.10(6), 361–367 (2004).
   PubMed Web of Science ®Google Scholar
• Aubry JM, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J. Clin. Psychiatry61(9), 649–655 (2000).
   PubMed Web of Science ®Google Scholar
• Rachid F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J. Clin. Psychiatry65(11), 1537–1545 (2004).
   PubMed Web of Science ®Google Scholar
• Baldassano CF, Ballas C, Datto SM et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipolar Disord.5(1), 72–75 (2003).
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl.212, 11–19 (1970).
   PubMedGoogle Scholar
• Barnes TRE. A rating scale for drug-induced akathisia. Br. J. Psychiatry154, 672–676 (1989).
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L; MOZART Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr. Res.113(1), 112–121 (2009).
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano R, O’Gorman C, Harrigan RH. Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotherapy30(2), 127–135 (2010).
   PubMed Web of Science ®Google Scholar
• Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Olanzapine alone or in combination for acute mania. Cochrane Database Syst. Rev.3, CD004040 (2003).
   Google Scholar
• Rendell JM, Gijsman HJ, Goodwin GM, Geddes GR. Risperidone alone or in combination for acute mania. Cochrane Database Syst. Rev.25(1), CD004043 (2006).
   Google Scholar
• Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variation to the phenotype of drug response. Mol. Psychiatry9, 442–473 (2004).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Fuhr U, Brockmöller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Nat. Rev. Drug. Discov.4, 639–647 (2005).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther.116(3), 496–526 (2007).
   PubMed Web of Science ®Google Scholar
• Campbell DB, Ebert PJ, Skelly T et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol. Psychiatry63, 32–41 (2008).
   PubMed Web of Science ®Google Scholar
• Omerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse events reaction to drug used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf.31(7), 597–607 (2008).
   PubMedGoogle Scholar
• Chaudhry I, Neelam K, Duddu V, Husain N. Ethnicity and psychopharmacology. J. Psychopharmacol.22(6), 673–680 (2008).
   PubMed Web of Science ®Google Scholar
• Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J. Clin. Psychiatry68, 1071–1077 (2007).
   PubMed Web of Science ®Google Scholar
• Citrome L. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. Expert Rev. Neurother.10(7), 1031–1037 (2010).
   PubMed Web of Science ®Google Scholar